arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

COGNITION THERAPEUTICS INC

CGTX
$1.07 ▼ -0.05 (-4.44%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
26 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

COGNITION THERAPEUTICS INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $95.4M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -23.3%
FCF / Share $-0.06
Trailing P/E
Price / Book 3.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-4.57M
↑ +46.1%
FCF / Share Free cash flow per share
$-0.06
↑ +61.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
13
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters